Detalhe da pesquisa
1.
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Clin Infect Dis
; 68(7): 1213-1222, 2019 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30759183
2.
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
EClinicalMedicine
; 37: 100976, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34386749
3.
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Vaccine
; 38(51): 8194-8199, 2020 12 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176935